Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.990 -0.180 (-8.29%)
Streaming Delayed Price Updated: 1:08 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Half 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
From Innate Pharma SA
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
Via InvestorPlace
News headline image
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2024 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma: Clarification Regarding SAR443579 Designation
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
News headline image
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.